Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04664595
Other study ID # 55-213-08-1-2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2012
Est. completion date December 2013

Study information

Verified date August 2021
Source Prince of Songkla University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

to evaluate and compare the effect-site concentration of propofol with the TCI system for second-generation SGA device insertion between the I-gel™, Supreme™, ProSeal™ and Laryngeal Tube Suction II™. to determine the hemodynamic changes during insertion of supraglottic devices in patients undergoing elective surgery and any complications after device insertion.


Description:

The investigators enrolled ASA physical status I-III patients who were 18-70 years old and scheduled for general anesthesia for elective non-cardiac surgery with SGA devices.Adults with a potentially difficult airway (cervical spine disease, Mallampati classification IV, or a mouth opening less than 2.5 cm.), reactive airway disease, signs of respiratory infection or a plan to remain intubated were excluded from the study. The investigators also excluded patients who had a risk of gastric aspiration or morbid obesity (body mass index > 35 kg/m2). Patients were randomized into 4 groups (I-gel™, Supreme™, ProSeal™ and Laryngeal Tube Suction II™ SGAs) according to a computer generated randomization list and patients were allocated consecutively. The sample size of each group required 10 patients. All patients were pre-oxygenated with 100% oxygen. After the administration of 2 µg/ml intravenous fentanyl for 5 minutes, anesthesia was induced with the Schnider pharmacokinetic TCI system. After equilibration of the plasma-site and effect-site concentrations in propofol TCI, 1 of the 4 types of SGA was randomly inserted by two anesthesiologists (resident trainee and staff doctor) who were unaware of the actual plasma concentration of propofol without the use of a muscle relaxant. The response of each patient determined the effect-site concentration of propofol of the next patient. "No Response" was defined as Laryngeal Mask Airway Insertion Score = 0 and "Response" was defined as Laryngeal Mask Airway Insertion Score ≥ 1. If the insertion of the supraglottic airway device was successful ("No Response"), then the target effect-site concentration was decreased by a step of 0.4 µg/ml. If the insertion failed ("Response"), the target effect-site concentration was increased by the same dose. The patients' responses to LMA insertion was classified by blinded investigators.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - ASA physical status I-III patients. - Patients 18-70 years old . - Patients scheduled for general anesthesia for elective non-cardiac surgery with SGA devices. Exclusion Criteria: - Adults with a potentially difficult airway (cervical spine disease, Mallampati classification IV, or a mouth opening less than 2.5 cm.). - Adults with reactive airway disease. - Adults with signs of respiratory infection or a plan to remain intubated were excluded from the study. - Excluded patients who had a risk of gastric aspiration or morbid obesity (body mass index > 35 kg/m2).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Propofol Fresenius
final dose of Propofol (mcg/kg) to reach the target effect-site concentration

Locations

Country Name City State
Thailand Price of Songkla University Hat Yai Songkhla
Thailand Songklanagarind Hospital Hat Yai Songkhla

Sponsors (1)

Lead Sponsor Collaborator
Prince of Songkla University

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tolerability of propofol for supragloqtic airway devices insertion The effect-site concentration of propofol required to insert supraglottic airway devices. 2 years
Secondary Blood pressure changes from baseline after insertion of supraglottic devices 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01376947 - Comparison of the Difficulty on Insertion of IUD Devices Between Nulliparous and Multiparous Women N/A
Completed NCT01367678 - Mucosal Pressure of the Laryngeal Mask Airway Supreme Versus the i-Gel in Paralyzed Anesthetized Female Patients N/A